OrthoPediatrics (NASDAQ:KIDS) Stock Price Up 10.3% – Time to Buy?

OrthoPediatrics Corp. (NASDAQ:KIDS)’s share price traded up 10.3% on Monday . The stock traded as high as $20.33 and last traded at $20.1950. 82,982 shares were traded during trading, a decline of 33% from the average session volume of 124,031 shares. The stock had previously closed at $18.31.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. JMP Securities cut their target price on shares of OrthoPediatrics from $35.00 to $25.00 and set a “market outperform” rating for the company in a research note on Friday, October 10th. Canaccord Genuity Group began coverage on OrthoPediatrics in a research note on Wednesday, December 10th. They issued a “buy” rating and a $24.00 price objective on the stock. Lake Street Capital decreased their target price on OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, October 10th. Stifel Nicolaus cut their price target on OrthoPediatrics from $32.00 to $20.00 and set a “buy” rating for the company in a report on Friday, October 10th. Finally, BTIG Research reiterated a “buy” rating and set a $23.00 price target on shares of OrthoPediatrics in a research report on Wednesday, October 29th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.00.

OrthoPediatrics Price Performance

The company has a current ratio of 7.40, a quick ratio of 3.52 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $504.30 million, a P/E ratio of -10.31 and a beta of 1.09. The company has a fifty day simple moving average of $17.63 and a two-hundred day simple moving average of $19.09.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Monday, January 9th. The company reported ($0.15) EPS for the quarter. The business had revenue of $25.08 million for the quarter. OrthoPediatrics had a negative return on equity of 6.86% and a negative net margin of 20.06%. Sell-side analysts expect that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On OrthoPediatrics

Institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after acquiring an additional 645 shares during the period. Millennium Management LLC increased its stake in OrthoPediatrics by 55.3% in the first quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock valued at $16,172,000 after purchasing an additional 233,873 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in OrthoPediatrics by 112.3% in the first quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock worth $4,937,000 after purchasing an additional 106,041 shares during the period. Jane Street Group LLC acquired a new stake in OrthoPediatrics in the first quarter worth $389,000. Finally, Harbor Capital Advisors Inc. raised its holdings in OrthoPediatrics by 116.5% in the second quarter. Harbor Capital Advisors Inc. now owns 333,959 shares of the company’s stock worth $7,173,000 after purchasing an additional 179,733 shares during the period. 69.05% of the stock is currently owned by institutional investors and hedge funds.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.